Cerus second-quarter product income for INTERCEPT Blood System increases 47 percent to $5.

At 30 June, 2010, the Company had cash, cash equivalents and short-term investments of $15.9 million, down from $19.9 million at December 31, 2009 and $19.0 million at March 31, 2010, leading to net cash consumption of $3.1 million for the next quarter. During the first quarter of 2010, the Company entered into a $10 million growth capital service and drew the initial $5 million from that facility. The second $5 million may be drawn down between September 30 and December 31, 2010, at the Company’s option. A fifth straight quarter of record product revenues reflects the raising familiarity of the INTERCEPT item in both routine use and clinical experience. Our technology is currently available to increasingly more patients, stated Claes Glassell, president and chief executive officer of Cerus Corporation.Despite the health officer’s false claims, there is ample evidence that vaping assists smokers quit and can be far less dangerous than smoking, Gregory Conley, president of the e-cigarette advocacy group American Vaping Association, said within an email. Smokers deserve truthful and accurate information about the relative dangers of different nicotine items, not hype and conjecture predicated on cherry-picked reports. The California report called for limitations on the sale and marketing of e-cigarettes, protections against accidental ingestion of liquid smoking and an scholarly education marketing campaign on the hazards of using e-cigarettes.